

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A liquid formulation comprising

- a) human ~~[[a]]~~ growth hormone (hGH), ~~or a substance, which stimulates release~~  
~~or potentiates the activity of endogenous hGH;~~
- b) polyethylene-polypropylene glycol;
- c) a citrate buffer; ~~[[and]]~~
- d) ~~a stabilizer~~ sucrose, and
- e) phenol.

Claims 2-4 (Cancelled).

Claim 5 (Currently Amended): The formulation according to claim 4, ~~comprising 1,~~  
wherein sucrose is present in a concentration ranging from 10 mg/ml to 100 mg/ml.

Claim 6 (Previously Presented): The formulation according to claim 1, comprising  
citrate in a concentration ranging from 1 to 100 mM.

Claim 7 (Previously Presented): The formulation according to claim 1, having a pH  
in the range of 5 to 7.

Claim 8 (Previously Presented): The formulation according to claim 1, comprising  
the polyethylene-polypropylene glycol in a concentration ranging from 0.5 to 5 mg/ml.

Claim 9 (Currently Amended): The formulation according to claim 1, wherein the polyethylene-polypropylene glycol is a block copolymer of ethylene oxide and propylene oxide pluronic polyol.

Claim 10 (Currently Amended): The formulation according to claim 9, wherein the ~~pluronic polyol is pluronic F68~~ propylene oxide block is sandwiched between two ethylene oxide blocks.

Claim 11 (Cancelled)

Claim 12 (Previously Presented): A formulation according to claim ~~[[11]]~~ 1, ~~comprising the preservative~~ wherein the phenol is present in a concentration ranging from 1 to 10 mg/ml.

Claims 13-14 (Cancelled).

Claim 15 (Currently Amended): The formulation according to claim 1, the formulation having a pH of 5.9 and consisting of r-hGH, sucrose, Poloxamer 188, citric acid, phenol and optionally water for injection.

Claims 16-17 (Cancelled).

Claim 18 (Previously Presented): A pharmaceutical composition comprising the formulation according to claim 1.

Claim 19 (Previously Presented): The liquid formulation according to claim 1, wherein the formulation is hermetically closed in a sterile condition within a container suited for storage before use.

Claim 20 (Previously Presented): The formulation according to claim 4, comprising sucrose in a concentration ranging from 20 mg/ml to 80 mg/ml.

Claim 21 (Previously Presented): The formulation according to claim 4, comprising sucrose in a concentration at about 60 mg/ml.

Claim 22 (Previously Presented): The formulation according to claim 1, comprising citrate in a concentration ranging from 5 to 50 mM.

Claim 23 (Previously Presented): The formulation according to claim 1, comprising citrate in a concentration ranging from 10 to 20 mM.

Claim 24 (Previously Presented): The formulation according to claim 1, having a pH in the range of 5.5 to 6.5.

Claim 25 (Previously Presented): The formulation according to claim 1, having a pH at about 6.

Claim 26 (Previously Presented): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration ranging from 1 to 2 mg/ml.

Claim 27 (Previously Presented): The formulation according to claim 1, comprising the polyethylene-polypropylene glycol in a concentration at 1.5 mg/ml.

Claim 28 (Previously Presented): A formulation according to claim 11, comprising the preservative in a concentration ranging from 2 to 5 mg/ml.

Claim 29 (Previously Presented): A formulation according to claim 11, comprising the preservative in a concentration at 3 mg/ml.